Back to Journals » Clinical Interventions in Aging » Volume 13

Some aspects need to be considered in assessment and treatment of sarcopenia

Authors Erdogan T, Bahat G

Received 4 June 2018

Accepted for publication 7 June 2018

Published 10 July 2018 Volume 2018:13 Pages 1231—1232

DOI https://doi.org/10.2147/CIA.S176216

Checked for plagiarism Yes

Editor who approved publication: Dr Richard Walker


Tugba Erdogan, Gulistan Bahat

Department of Internal Medicine, Division of Geriatrics, Istanbul University, Istanbul Medical School, Istanbul, Turkey

We have read the review article by Ilaria Liguori et al1 with great interest. In this article, authors aimed to review sarcopenia in terms of assessment of its burden and strategies to improve outcomes. We have some comments that would contribute on this extensive review. Authors reported that the diagnosis of sarcopenia requires the presence of both low muscle mass and low muscle function. Authors defined low muscle function as gait speed lower than 0.8 m/s and/or a grip strength lower than 26–30 kg for men and 16–20 kg for women. However, it should be noted that European Working Group on Sarcopenia in Older People (EWGSOP) recommends use of normative data of the study population for muscle mass and muscle strength cutoff points. After EWGSOP publication, population-specific cutoff values, including the Turkish and Korean population, have been published and better to be included in a paper aimed to review sarcopenia in this context.2

View the original paper by Liguori and colleagues.

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]